Similar articles

• Anti-adhesion cancer therapy.

  Glinsky GV. Glinsky GV. Cancer Metastasis Rev. 1998 Jun;17(2):177-85. doi: 10.1023/a:1006050302406. Cancer Metastasis Rev. 1998. PMID: 9770114 Review. No abstract available.
• Peptide array-based screening of human mesenchymal stem cell-adhesive peptides derived from fibronectin type III domain.

  Okochi M, Nomura S, Kaga C, Honda H. Okochi M, et al. Biochem Biophys Res Commun. 2008 Jun 20;371(1):85-9. doi: 10.1016/j.bbrc.2008.04.019. Epub 2008 Apr 14. Biochem Biophys Res Commun. 2008. PMID: 18413142
• Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.

  Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T, Yantiri-Wernimont F, Frederickson S, Bowdish KS, Xin H. Siva AC, et al. Cancer Res. 2008 May 15;68(10):3759-66. doi: 10.1158/0008-5472.CAN-07-1657. Cancer Res. 2008. PMID: 18483259
• Nb rat prostate adenocarcinoma model: metastasis.

  Drago JR, Curley RM, Sipio JC. Drago JR, et al. Anticancer Res. 1985 Mar-Apr;5(2):193-6. Anticancer Res. 1985. PMID: 2581494
• Role of the EpCAM (CD326) in prostate cancer metastasis and progression.

  Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, Li Y. Ni J, et al. Cancer Metastasis Rev. 2012 Dec;31(3-4):779-91. doi: 10.1007/s10555-012-9389-1. Cancer Metastasis Rev. 2012. PMID: 22718399 Review.